Does declining kidney function raise homocysteine and cardiovascular risk?

Elevated homocysteine (tHcy) serves as a critical bridge between declining kidney function and increased cardiovascular vulnerability. In patients with chronic kidney disease (CKD), the relationship between renal clearance and metabolic health is well-documented and scientifically supported.

Renal clearance and homocysteine levels

As the estimated glomerular filtration rate (eGFR) declines, plasma homocysteine levels rise progressively. The kidneys are the primary site for homocysteine removal, responsible for 60%–70% of its clearance through tubular extraction and subsequent metabolism.

• Filtration and metabolism: While glomerular filtration handles approximately 10%–15% of unbound homocysteine, the more critical driver in CKD is the impairment of proximal tubular metabolism (remethylation and transsulfuration).
• Correlation: Research shows a strong inverse correlation between eGFR and tHcy, with hyperhomocysteinemia becoming prevalent from CKD stage 2 onward.

Endothelial dysfunction mechanisms

Higher homocysteine levels trigger vascular damage through several molecular pathways that impair the inner lining of blood vessels.

• Nitric oxide inhibition: Homocysteine inhibits the enzyme DDAH, leading to an accumulation of asymmetric dimethylarginine (ADMA). ADMA competes with L-arginine to inhibit endothelial nitric oxide synthase (eNOS), significantly reducing nitric oxide bioavailability.
• Oxidative and ER stress: tHcy increases reactive oxygen species (ROS) and triggers the unfolded protein response (ER stress), leading to mitochondrial dysfunction and pro-apoptotic signaling in endothelial cells.
• Protein modification: The metabolite homocysteine-thiolactone modifies proteins, further compromising vascular integrity and promoting inflammation.

Cardiovascular risk and clinical implications

The accumulation of homocysteine translates into a quantifiable increase in clinical cardiovascular risk.

• Mortality and CHD: Meta-analyses demonstrate that higher homocysteine categories are associated with a 68% increase in cardiovascular mortality and a 66% increase in coronary heart disease (CHD) mortality.
• Dose-response: Studies indicate that every 5 μmol/L increase in serum homocysteine is linked to a 52% higher mortality risk, mediated by accelerated atherosclerosis and plaque instability.

Bottom line

Reduced renal clearance (low eGFR) leads to elevated homocysteine, which causes endothelial dysfunction by reducing nitric oxide and increasing oxidative stress. This sequence significantly elevates the risk for coronary artery disease and cardiovascular mortality.